# Extended-release Buprenorphine as a Novel Low-dose Induction Strategy

> **NCT06441604** · PHASE2 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** Extended-release Buprenorphine

## Key facts

- **NCT ID:** NCT06441604
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441604, "Extended-release Buprenorphine as a Novel Low-dose Induction Strategy". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06441604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*